公开(公告)号：US20190202926A1

公开(公告)日：2019-07-04

申请号：US15780285

申请日：2016-12-01

Applicant: GENMAB B.V.

Inventor： Frank BEURSKENS ,  Marije OVERDIJK ,  Rob DE JONG ,  David SATIJN ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/30

CPC classification number: C07K16/2878 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/507 ,  A61P35/00 ,  C07K16/30 ,  C07K16/46 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/73 ,  C07K2317/75 ,  C12N15/62

Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind antigens of Death Receptors, which are members of the tumor necrosis factor (TNF) receptor Superfamily (TNFR-SF) with an intracellular death domain. The invention relates in particular to antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after target binding. The invention further relates to a combination of antibody molecules binding different epitopes on one or more specific Death Receptors. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

公开(公告)号：US20150175707A1

公开(公告)日：2015-06-25

申请号：US14413178

申请日：2013-07-05

Applicant: GENMAB B.V.

Inventor： Rob N. De Jong ,  Frank Beurskens ,  Paul Parren ,  Aran Frank Labrijn ,  Janine Schuurman ,  Arjen Vlug ,  Sandra Verploegen

IPC: C07K16/40 ,  C07K16/12 ,  C07K16/28

Abstract: The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.

Abstract translation: 本发明涉及包含不同于存在于人IgG1中的三个不同位置的氨基酸的二聚体蛋白质。 所述二聚体蛋白中的六个能够在溶液中形成六聚体结构。

公开(公告)号：US20240141057A1

公开(公告)日：2024-05-02

申请号：US18461910

申请日：2023-09-06

Applicant: GENMAB B.V.

Inventor： Claudine Brigitte Fernande Vermot-Desroches ,  Olivier Frédéric Subiger ,  Laurence Françoise Jeanne-Marie Bourdin

IPC: C07K16/28

CPC classification number: C07K16/2878 ,  A61K2039/507

Abstract: Anti-DR5 family member antibodies and bispecific antibodies comprising one or more anti-DR5 family member antibodies are disclosed. These antibodies can be used to trigger cell death on DR5 positive cells.

公开(公告)号：US20220411529A1

公开(公告)日：2022-12-29

申请号：US17774333

申请日：2020-11-06

Applicant: GENMAB B.V.

Inventor： Rob DE JONG ,  Frank BEURSKENS ,  Gijs ZOM ,  Janine SCHUURMAN ,  Xiaoguang XUE

IPC: C07K16/28

Abstract: The invention relates to combination therapy involving two or more antibodies, wherein the Fc regions of the two antibodies have been modified such that hetero-oligomerization between the antibodies is strongly favored over self-oligomerization when antibodies are bound to their corresponding target antigens and such that hetero-oligomerization-independent effector functions of one or both antibodies are eliminated or strongly reduced. The invention also relates to antibodies, compositions, and kits suitable for use in the combination therapy of the invention.

公开(公告)号：US20220332801A1

公开(公告)日：2022-10-20

申请号：US17534712

申请日：2021-11-24

Applicant: GENMAB B.V.

Inventor： Annemarie KUIPERS ,  Kok VAN KESSEL ,  Frank BEURSKENS ,  Rob DE JONG ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Paul PARREN ,  Jos VAN STRIJP ,  Suzan ROOIJAKKERS

IPC: C07K16/12 ,  A61P31/04

Abstract: The present invention relates to antibody molecules that bind to Wall Teichoic Acid (WTA) or Capsular Polysaccharides (CP) such as Capsular Polysaccharides type 5 (CP5). The invention relates in particular to antibody molecules of the IgG isotype having a mutation in the Fc domain that enhances clustering of IgG molecules after target binding. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of infectious diseases using these compositions

公开(公告)号：US20210107988A1

公开(公告)日：2021-04-15

申请号：US16963701

申请日：2019-01-24

Applicant: GENMAB B.V.

Inventor： Simone OOSTINDIE ,  Andreas HOLLENSTEIN ,  Frank BEURSKENS ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Rob DE JONG

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to combination therapy involving two or more Fc region-containing antigen-binding polypeptides, such as antibodies, wherein the polypeptides have been modified such that hetero-oligomerization between the polypeptides is strongly favored over homo-oligomerization when the polypeptides are bound to their corresponding target antigens. The invention also relates to polypeptides, compositions, kits and devices suitable for use in the combination therapy of the invention.

公开(公告)号：US20190276549A1

公开(公告)日：2019-09-12

申请号：US16345044

申请日：2017-11-01

Applicant: GENMAB B.V.

Inventor： Rob DE JONG ,  Frank BEURSKENS ,  Marije OVERDIJK ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/28 ,  A61P35/00 ,  A61P37/06 ,  A61P31/04 ,  A61P31/12 ,  A61P31/10

Abstract: Described herein are polypeptides and antibodies comprising a variant Fc region. The variant Fc region provides for stabilized Fc-Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, while at the same time also having decreased complement-dependent cytotoxicity (CDC) and may also have decreased activation of other effector functions resulting from one or more amino acid modifications in the Fc region.

公开(公告)号：US20190144554A1

公开(公告)日：2019-05-16

申请号：US15780268

申请日：2016-12-01

Applicant: GENMAB B.V.

Inventor： Marije OVERDIJK ,  Kristin STRUMANE ,  Rik RADEMAKER ,  Esther BREIJ ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/28 ,  C07K16/46 ,  C12N15/62 ,  C07K16/30 ,  A61P35/00

Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

公开(公告)号：US20230293680A1

公开(公告)日：2023-09-21

申请号：US18017241

申请日：2021-07-23

Applicant: Genmab B.V.

Inventor： Hilma VAN DER HORST ,  Tuna MUTIS ,  Kristin STRUMANE ,  Esther BREIJ ,  Marije OVERDIJK

IPC: A61K39/395 ,  A61K31/454 ,  A61K31/69 ,  A61P35/00

CPC classification number: A61K39/3955 ,  A61K31/454 ,  A61K31/69 ,  A61P35/00 ,  A61K2039/507

Abstract: The present invention relates to the treatment of multiple myeloma using a combination of two antibody molecules that bind to human DR5 antigen and an immunomodulatory imide dmg. The present invention further relates to treatment of relapsed and/or refectory multiple myeloma.

公开(公告)号：US20220411522A1

公开(公告)日：2022-12-29

申请号：US17684238

申请日：2022-03-01

Applicant: GENMAB B.V.

Inventor： Frank BEURSKENS ,  Marije OVERDIJK ,  Rob DE JONG ,  David SATIJN ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  C12N15/62

Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind antigens of Death Receptors, which are members of the tumor necrosis factor (TNF) receptor Superfamily (TNFR-SF) with an intracellular death domain. The invention relates in particular to antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after target binding. The invention further relates to a combination of antibody molecules binding different epitopes on one or more specific Death Receptors. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.